Physician profile
Yves Brignol
NPI 1396742748
$6,068.49
in general payments reported to CMS, 2019-2025
24 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $273 · 2021: $145 · 2022: $501 · 2023: $1,094 · 2024: $1,831 · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,856 · Education: $10.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,855.84 |
| Education | $10.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,065.01 | 2020-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $709.52 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $590.85 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $559.78 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $507.59 | 2019-2024 | Rayaldee |
| Ardelyx, INC. | $503.63 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Amgen INC. | $400.19 | 2024-2025 | Krystexxa, Tavneos |
| Fresenius USA Marketing, INC. | $387.04 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $198.04 | 2022-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $169.01 | 2022-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $158.73 | 2023-2024 | Acthar |
| Janssen Pharmaceuticals, INC | $124.98 | 2021 | |
| Alexion Pharmaceuticals, INC. | $120.51 | 2019-2025 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $109.78 | 2023-2025 | |
| Outset Medical INC | $100.82 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.64 | 2023-2025 | |
| Lilly USA, LLC | $71.08 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $47.20 | 2023 | Jesduvroq, Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.19 | 2025 | Jardiance |
| Scpharmaceuticals INC. | $36.82 | 2025 | |
| Ani Pharmaceuticals, INC. | $34.37 | 2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $27.29 | 2023 | Krystexxa |
| Akebia Therapeutics INC | $17.97 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.45 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yves Brignol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.